XTMAB-16

N/A

Report date: 2023/12/22 20:09:58

Base Information

Drug NameXTMAB-16
Drug Alias NameXTMAB-16
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Tumor necrosis factor α
TargetsTumor necrosis factor α
Therapy Area/IndicationsSarcoidosis, Pulmonary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesPoland +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesXentria Inc
China Registration ClassN/A

Develop Information

Active CompaniesMeitheal Pharmaceuticals IncXentria Inc
Inactive CompaniesN/A
Active IndicationsSarcoidosis, Pulmonary
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A